What Are Breast Tumors?

Breast tumors are abnormal growths of tissue arising within the breast, classified as benign or malignant based on their cellular behavior, invasive potential, and ability to metastasize. Malignant breast tumors constitute the most common cancer diagnosis among women globally, making their detection, classification, and treatment a major focus of biomedical engineering research. Engineering contributions span imaging system design, signal and image processing algorithms, and computational methods for pathology interpretation.

Tumor formation in the breast typically originates in the ductal or lobular epithelium. Ductal carcinoma, which arises in the milk ducts, is the most prevalent form of breast cancer, while lobular carcinoma begins in the milk-producing lobules. Benign tumors, including fibroadenomas, adenosis, and phyllodes tumors, do not invade surrounding tissue but may require clinical follow-up or removal depending on size and histological features.

Classification and Pathology

The pathological classification of breast tumors draws on histological grading, receptor status, and molecular subtype profiling. Tumors are graded on the Nottingham scale from 1 to 3 based on cellular differentiation, mitotic activity, and nuclear pleomorphism. Receptor status, specifically estrogen receptor, progesterone receptor, and HER2/neu expression, determines eligibility for targeted therapies and forms the basis of molecular subtype categories including luminal A, luminal B, HER2-enriched, and triple-negative. This classification framework, combining histological and molecular criteria, directly informs treatment planning and prognosis. Research compiled in a PMC review of machine learning techniques for breast cancer classification documents how computational methods are being applied to automate and standardize this classification process.

Detection and Imaging

Early detection of breast tumors relies on imaging modalities that can localize and characterize lesions before they become palpable. X-ray mammography is the established screening tool, with digital breast tomosynthesis adding three-dimensional reconstruction to reduce overlapping tissue artifacts. Ultrasound is used to differentiate solid from cystic lesions, and MRI provides high-sensitivity assessment for high-risk patients or preoperative staging. A dataset described in an IEEE Xplore publication on breast cancer histopathological images introduced a benchmark collection of annotated microscopy images that has supported reproducible benchmarking of automated classification algorithms. Photoacoustic imaging, which detects vascular signatures of tumor angiogenesis, is an emerging non-ionizing modality undergoing clinical evaluation.

Computational Analysis and Deep Learning

Deep learning has substantially advanced automated tumor detection, segmentation, and grading. Convolutional neural networks applied to mammographic images have achieved diagnostic performance comparable to that of radiologists in controlled studies. For histopathological slides, models trained on whole-slide images can identify tumor regions, predict grade, and infer molecular subtype from staining patterns alone. A study in Scientific Reports on multimodal deep learning for breast cancer screening demonstrated that combining mammographic and ultrasound imaging within a single deep-learning framework improves classification accuracy beyond either modality alone. These methods are being evaluated for clinical decision-support applications, where they could assist radiologists and pathologists in high-volume screening programs.

Applications

Breast tumor research has applications across a range of clinical and engineering domains, including:

• Automated screening systems using mammography and ultrasound
• Computer-aided detection software for radiology workstations
• Image-guided biopsy and surgical excision systems
• Radiation therapy planning using tumor volume delineation
• Drug response prediction from pre-treatment imaging biomarkers